Gene expression profiles of inflammatory breast cancer: Correlation with response to neoadjuvant chemotherapy and metastasis-free survival

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 358-365

  Bertucci, F ^a   Ueno, N T ^b   Finetti, P ^a   Vermeulen, P ^c   Lucci, A ^b   Robertson, F M ^b   Marsan, M ^c,d   Iwamoto, T ^b   Krishnamurthy, S ^b   Masuda, H ^b   Van Dam, P ^c   Woodward, W A ^b   Cristofanilli, M ^e   Reuben, J M ^b   Dirix, L ^c   Viens, P ^a   Symmans, W F ^b   Birnbaum, D ^a   Van Laere, S J ^c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SINT AUGUSTINUS HOSPITAL   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Gene expression; Inflammatory breast cancer; Profiling; Prognosis; Response to chemotherapy

Indexed keywords

ANTHRACYCLINE; INTERFERON; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATIONAL STUDY; DISTANT METASTASIS FREE SURVIVAL; DNA MICROARRAY; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HUMAN; INFLAMMATORY BREAST CANCER; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; TUMOR IMMUNITY; VALIDATION STUDY; ADJUVANT CHEMOTHERAPY; CARCINOMA, DUCTAL, BREAST; DISEASE FREE SURVIVAL; FEMALE; GENETICS; INFLAMMATORY BREAST NEOPLASMS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATORY BREAST NEOPLASMS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; TRANSCRIPTOME;

EID: 84893408821     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt496     Document Type: Article

References (26)

1. Robertson FM, Bondy M, Yang W et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 2010; 60: 351-375.
2. Charafe-Jauffret E, Tarpin C, Viens P et al. Defining the molecular biology of inflammatory breast cancer. Semin Oncol 2008; 35: 41-50.
3. Bekhouche I, Finetti P, Adelaide J et al. High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. PLoS One 2011; 6: e16950.
4. Bertucci F, Finetti P, Rougemont J et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004; 64: 8558-8565.
5. Bertucci F, Finetti P, Rougemont J et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005; 65: 2170-2178.
6. Bieche I, Lerebours F, Tozlu S et al. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004; 10: 6789-6795.
7. Boersma BJ, Reimers M, Yi M et al. A stromal gene signature associated with inflammatory breast cancer. Int J Cancer 2008; 122: 1324-1332.
8. Dressman HK, Hans C, Bild A et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 2006; 12: 819-826.
9. Nguyen DM, Sam K, Tsimelzon A et al. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 2006; 12: 5047-5054.
10. Van Laere S, Van der Auwera I, Van den Eynden GG et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 2005; 93: 237-246.
11. Bertucci F, Finetti P, Birnbaum D et al. Gene expression profiling of inflammatory breast cancer. Cancer 2010; 116: 2783-2793.
12. Van Laere S, Ueno NT, Finetti P et al. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression data sets. Clin Cancer Res 2013; 19: 4685-4696.
13. Dawood S, Merajver SD, Viens P et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011; 22: 515-523.
14. Chevallier B, Chollet P, Merrouche Y et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995; 13: 1564-1571.
15. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
16. Prat A, Parker JS, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
17. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
18. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
19. Chang HY, Sneddon JB, Alizadeh AA et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004; 2: E7.
20. Liu R, Wang X, Chen GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356: 217-226.
21. Nielsen TO, Parker JS, Leung S et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 5222-5232.
22. Farmer P, Bonnefoi H, Anderle P et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15: 68-74.
23. Hess KR, Anderson K, Symmans WF et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24: 4236-4244.
24. Gianni L, Zambetti M, Clark K et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23: 7265-7277.
25. Straver ME, Glas AM, Hannemann J et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010; 119: 551-558.
26. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.